Latest News Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears By Staff Wednesday, May 3, 2017 12:15 AM SAN DIEGO, Calif. and SEATTLE, Wash.—Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, and SightLife Surgical, a cornea-focused organization providing services to ophthalmic surgeons, announced the signing of an exclusive strategic sales and marketing agreement. Under the agreement, SightLife Surgical will deploy their sales team to offer Imprimis’ Serum Tears compounded formulations to physicians, large practice groups, surgery centers, hospitals and health care organizations nationwide. Imprimis’ Serum Tears autologous serum eye drops (ASEDs) are prescribed for chronic dry eye patients who do not respond to traditional dry eye treatments. Mark L. Baum, CEO of Imprimis, said, “Our goals in 2017 include the roll-out of a formidable array of offerings to compete in the three largest U.S. ophthalmic markets: cataract surgery, glaucoma and dry eye. We are pleased to have accelerated the first phase of the launch of our dry eye program by partnering with the largest and most prestigious eye bank in the world. Partnering with SightLife Surgical represents an important step in our strategic plan to efficiently expand our sales presence and increase our growing customer base.” SightLife Surgical provides corneal tissue and medical devices to surgeons around the world who are performing corneal transplant procedures. Serum Tears may be used as a preventative treatment of a transplant for patients who suffer from corneal abrasions caused by dry eye, which makes it a valuable product for the surgeons they serve, the announcement said.“With the assistance of the Imprimis team, we intend to train and deploy our sales team on this innovative product for severe dry eye disease,” said Monty Montoya, president and CEO of SightLife Surgical. “This partnership with Imprimis uniquely positions us to help the thousands of domestic physicians treating dry eye and makes this important product widely available to patients in need of these drops across the country,” Montoya said.